Literature DB >> 1971109

Molecular basis for dominantly inherited inclusion body beta-thalassemia.

S L Thein1, C Hesketh, P Taylor, I J Temperley, R M Hutchinson, J M Old, W G Wood, J B Clegg, D J Weatherall.   

Abstract

Analysis of the molecular basis of dominantly inherited beta-thalassemia in four families has revealed different mutations involving exon 3 of the beta-globin gene. It is suggested that the phenotypic difference between this condition and the more common recessive forms of beta-thalassemia lies mainly in the length and stability of the abnormal translation products that are synthesized and, in particular, whether they are capable of binding heme and producing aggregations that are relatively resistant to proteolytic degradation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971109      PMCID: PMC54016          DOI: 10.1073/pnas.87.10.3924

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  A novel globin structural mutant, Showa-Yakushiji (beta 110 Leu-Pro) causing a beta-thalassemia phenotype.

Authors:  Y Kobayashi; Y Fukumaki; N Komatsu; Y Ohba; T Miyaji; Y Miura
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

2.  Heterozygous beta thalassaemia of unusual severity.

Authors:  S Friedman; S Ozsoylu; R Luddy; E Schwartz
Journal:  Br J Haematol       Date:  1976-01       Impact factor: 6.998

3.  One form of inclusion body beta-thalassemia is due to a GAA----TAA mutation at codon 121 of the beta chain.

Authors:  Y J Fei; T A Stoming; A Kutlar; T H Huisman; G Stamatoyannopoulos
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  Molecular characterization of a high A2 beta thalassemia by direct sequencing of single strand enriched amplified genomic DNA.

Authors:  S L Thein; C Hesketh; J M Brown; A V Anstey; D J Weatherall
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

6.  A genetically determined disorder with features both of thalassaemia and congenital dyserythropoietic anaemia.

Authors:  D J Weatherall; J B Clegg; H H Knox-Macaulay; C Bunch; C R Hopkins; I J Temperley
Journal:  Br J Haematol       Date:  1973-06       Impact factor: 6.998

7.  Characterization of a spontaneous mutation to a beta-thalassemia allele.

Authors:  H H Kazazian; S H Orkin; C D Boehm; S C Goff; C Wong; C E Dowling; P E Newburger; R G Knowlton; V Brown; H Donis-Keller
Journal:  Am J Hum Genet       Date:  1986-06       Impact factor: 11.025

8.  Inclusion body beta-thalassemia trait in a Swiss family is caused by an abnormal hemoglobin (Geneva) with an altered and extended beta chain carboxy-terminus due to a modification in codon beta 114.

Authors:  P Beris; P A Miescher; J C Diaz-Chico; I S Han; A Kutlar; H Hu; J B Wilson; T H Huisman
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

9.  Inclusion-body beta-thalassemia trait. A form of beta thalassemia producing clinical manifestations in simple heterozygotes.

Authors:  G Stamatoyannopoulos; R Woodson; T Papayannopoulou; D Heywood; S Kurachi
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

10.  Hemoglobin Cranston, an unstable variant having an elongated beta chain due to nonhomologous crossover between two normal beta chain genes.

Authors:  H F Bunn; G J Schmidt; D N Haney; R G Dluhy
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

View more
  35 in total

1.  Splicing and 3' end formation in the definition of nonsense-mediated decay-competent human beta-globin mRNPs.

Authors:  G Neu-Yilik; N H Gehring; R Thermann; U Frede; M W Hentze; A E Kulozik
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

2.  Rapid molecular characterization of mutations leading to unstable hemoglobin beta-chain variants.

Authors:  E Girodon; N Ghanem; M Vidaud; J Riou; J Martin; F Galactéros; M Goossens
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

3.  Beta-thalassaemia: molecular pathogenesis and clinical variability.

Authors:  A E Kulozik
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

4.  Slide PCR: DNA amplification from cell samples on microscopic glass slides.

Authors:  E P Yap; J O McGee
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

Review 5.  Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors.

Authors:  Pamela Nicholson; Hasmik Yepiskoposyan; Stefanie Metze; Rodolfo Zamudio Orozco; Nicole Kleinschmidt; Oliver Mühlemann
Journal:  Cell Mol Life Sci       Date:  2009-10-27       Impact factor: 9.261

6.  Binary specification of nonsense codons by splicing and cytoplasmic translation.

Authors:  R Thermann; G Neu-Yilik; A Deters; U Frede; K Wehr; C Hagemeier; M W Hentze; A E Kulozik
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

7.  Mechanism of escape from nonsense-mediated mRNA decay of human beta-globin transcripts with nonsense mutations in the first exon.

Authors:  Gabriele Neu-Yilik; Beate Amthor; Niels H Gehring; Sharif Bahri; Helena Paidassi; Matthias W Hentze; Andreas E Kulozik
Journal:  RNA       Date:  2011-03-09       Impact factor: 4.942

Review 8.  Hemoglobin variants: biochemical properties and clinical correlates.

Authors:  Christopher S Thom; Claire F Dickson; David A Gell; Mitchell J Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

Review 9.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

10.  Hereditary eosinophil peroxidase deficiency: immunochemical and spectroscopic studies and evidence for a compound heterozygosity of the defect.

Authors:  M Romano; P Patriarca; C Melo; F E Baralle; P Dri
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.